indium has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amaral-Júnior, JC; Carvalho, IC; Carvalho, SM; Mansur, AAP; Mansur, HS | 1 |
| Gu, W; Hanaoka, H; Katsumata, N; Tsushima, Y; Yudistiro, R | 1 |
2 other study(ies) available for indium and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Cu-In-S/ZnS@carboxymethylcellulose supramolecular structures: Fluorescent nanoarchitectures for targeted-theranostics of cancer cells.
Topics: Antineoplastic Agents; Carboxymethylcellulose Sodium; Copper; Female; Fluorescent Dyes; Humans; Indium; Quantum Dots; Sulfides; Sulfur; Theranostic Nanomedicine; Triple Negative Breast Neoplasms; Tumor Cells, Cultured; Zinc Compounds | 2020 |
Potential of three-step pretargeting radioimmunotherapy using biotinylated bevacizumab and succinylated streptavidin in triple-negative breast cancer xenograft.
Topics: Animals; Antineoplastic Agents, Immunological; Bevacizumab; Biotin; Dose-Response Relationship, Immunologic; Female; Heterografts; Immunoconjugates; Indium; Indium Radioisotopes; Kidney; Mice; Mice, Inbred BALB C; Mice, Nude; Radioimmunotherapy; Streptavidin; Succinimides; Triple Negative Breast Neoplasms | 2021 |